52-Year old patient with subcutaneous tumour under immunosuppressive therapy;52-Jähriger patient mit subkutaner raumforderung unter immunsuppression

Internist

Volumn 44, Issue 6, 2003, Pages 740-745

  Kolligs, F T ^a   Gerbes, A L ^b   Durr E M ^b   Schauer, R ^b   Kessler, M ^b   Jelinek, T ^b   Loscher T ^b   Bilzer, M ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Echinococcosis; Hepatitis C; Immunosuppression; Interferone; Liver transplantation

Indexed keywords

ALBENDAZOLE; ALPHA2B INTERFERON; IMMUNOSUPPRESSIVE AGENT; RIBAVIRIN; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ECHINOCOCCOSIS; ECHINOCOCCUS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LARVA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; SUBCUTANEOUS TISSUE TUMOR; TREATMENT OUTCOME;

EID: 0038008750     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-0862-3     Document Type: Article

References (14)

1. Ahmed A, Keeffe EB (2001) Hepatitis C virus and liver transplantation. Clin Liver Dis 5:1073-1090
2. Ammann RW, Eckert J (1996) Cestodes. Echinococcus. Gastroenterol Clin North Am 25:655-689
3. Bilzer M, Rau HG, Schauer R, Gerbes AL (2000) Lebertransplantation - Indikationsstellung und Probleme in der internistischen Nachsorge. Bay Int 20:212-222
4. Bresson-Hadni S, Koch S, Beurton I et al. (1999) Primary disease recurrence after liver transplantation for alveolar echinococcosis: Long-term evaluation in 15 patients. Hepatology 30:857-864
5. Eckert J, Deplazes P (1999) Alveolar echinococcosis in humans: the current situation in Central Europe and the need for countermeasures. Parasitol Today 15:315-319
6. Gottstein B (2000) Epidemiologie und Systematik der cystischen und alveolären Echinokokkose. Chirurg 71:1-8
7. Harraga S, Godot V, Bresson-Hadni S, Pater C, Beurton I, Bartholomot B, Vuitton DA (1999) Clinical efficacy of and switch from T helper 2 to T helper 1 cytokine profile after Interferon α2a monotherapy for human Echinococcosis. Clin Infect Dis 29:205-206
8. Ioppolo S, Notargiacomo S, Profumo E, Franchi C, Ortona E, Rigano R, Siracusano A (1996) Immunological responses to antigen B from Echinococcuc granulosus cyst fluid in hydatid patients. Parasite Immunol 18:571-578
9. Ito A, Ma L, Schantz PM et al. (1999) Differential serodiagnosis for cystic and alveolar echinococcosis using fractions of Echinococcus granulosus cyst fluid (antigen B) and E.multilocularis protoscolex (EM18). Am J Trop Med Hyg 60:188-192
10. Jenne L, Kilwinski J, Radloff P, Flick W, Kern P (1998) Clinical efficacy of and immunologic alterations caused by Interferon γ therapy for alveolar echinococcosis. Clin Infect Dis 26:492-494
11. Reuter S, Jensen B, Buttenschoen K, Kratzer W, Kern P (2000) Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. J Antimicrob Chemother 46:451-456
12. Reuter S, Seitz HM, Kern P, Junghanss T (2000) Extrahepatic alveolar echinococcosis without liver involvement: a rare manifestation. Infection 28:187-192
13. Schmid M, Samonigg H, Stöger H, Auer H, Sternthal MH, Wilders-Truschnig M, Reisinger EC (1995) Use of Interferon γ and mebendazole to stop the progression of alveolar hydatid disease: Case report. Clin Infect Dis 20:1543-1546
14. WHO Informal Working Group on Echinococcosis (1996) Guidelines for treatment of cystic and alveolar echinococcosis in humans. Bull Wld Hlth Org 74:231-242